Clinical Trial Update: Adrecizumab in Cardiogenic Shock [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Adrecizumab in cardiogenic shock, spanning Phase 2 and Phase 3, with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock
• Endothelial Dysfunction

Drugs mentioned

• Adrecizumab

Snippet

Sponsor: Dr. med. Mahir Karakas | Conditions: Cardiogenic Shock, Endothelial Dysfunction | Phase 2, Phase 3 | Status: COMPLETED